TransGeno in collaboration with Tartu Biotechnology Park (https://biopark.ee/?lang=en), organised a meeting on 21st May 2019 to engage with start up companies to discuss development of new tools for facilitation of “Biomarker Discovery”. Biomarkers are potential prognostic, diagnostic, and treatment indicators that despite their increasing potential for precision medicine, their development into commercial products is very challenging.

During this Meeting Dr. Sven Parkel described the efforts of a new Baltic Sea Region (BSR) consortium to create tools for supporting and overcoming the challenges of biomarker commercialization.